Are current diagnostic guidelines delaying early detection of dysglycemic states? Time for new approaches

Endocrine

Volumn 44, Issue 1, 2013, Pages 66-69

  Bergman, Michael ^a   Dankner, Rachel ^b,c,d   Roth, Jesse ^d,e,f,g   Narayan, K M Venkat ^h  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e Elmezzi Graduate School of Molecular Medicine   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h EMORY UNIVERSITY   (United States)

Author keywords

1,5 Anhydroglucitol; Adiponectin; Diabetes mellitus; Diabetes prevention; Dysglycemia; HbA1c; IL 1 receptor antagonist; Impaired fasting glucose; Impaired glucose tolerance; Interleukin 1 ; Prediabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ARTICLE; DIABETES MELLITUS; DIAGNOSTIC TEST; DYSGLYCEMIA; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

DELAYED DIAGNOSIS; DIABETES MELLITUS; DIAGNOSTIC TECHNIQUES, ENDOCRINE; EARLY DIAGNOSIS; GLUCOSE; GLUCOSE METABOLISM DISORDERS; HUMANS; INSULIN-SECRETING CELLS; PRACTICE GUIDELINES AS TOPIC; PREDIABETIC STATE; REFERENCE VALUES;

EID: 84881165991     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9873-6     Document Type: Article

References (21)

1. E.P. Joslin, The prevention of diabetes mellitus. JAMA 76(2), 79-84 (1921)
2. C.C. Cowie, K.F. Rust, E.S. Ford, M.S. Eberhardt, D.D. Byrd-Holt, C. Li, D.E. Williams, E.W. Gregg, K.E. Bainbridge, S.H. Saydah, L.S. Geiss, Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 32(2), 287-294 (2009)
3. K. Shaye, T. Amir, S. Shlomo, S. Yechezkel, Fasting glucose levels within the high normal range predict cardiovascular outcome. Am. Heart J. 164(7), 111-116 (2012)
4. J.A. Laukkanen, T.H. Mäkikallio, K. Ronkainen, J. Karppi, S. Kurl, Impaired fasting plasma glucose and type 2 diabetes are related to the risk of out-of-hospital sudden cardiac death and all-cause mortality. Diabetes Care (2012). doi: 10.2337/dc12-0110
5. The International Expert Committee, International Expert Committee Report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 32(7), 1327-1334 (2009)
6. T. Higgins, HbA1c for screening and diagnosis of diabetes mellitus. Endocrine (2012). doi: 10.1007/s12020-012-9768-y
7. R. Dankner, M. Bergman, A. Danoff, S. Qureshi, I. Whitford, N. Kaviani, Y. Dynkevich, J. Roth, The metabolic deterioration that antedates diabetes: Personal trajectories of HbA1c and fasting glucose as early indicators and possible triggers for intervention. Diabetes Metab. Res. Rev 29(1), 1-7 (2013). doi: 10.1002/dmrr.2373
8. E. Ferrannini, The stunned β cell: a brief history. Cell Metab. 11(5), 349-352 (2010)
9. M. Bergman, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine (2012). doi: 10.1007/s12020-9830-9
10. C. Talchai, S. Xuan, H.V. Lin, L. Sussei, D. Accili, Pancreatic β cell differentiation as a mechanism of diabetic β cell failure. Cell 150(6), 1223-1234 (2012)
11. A.G. Tabák, M. Jokela, T.N. Akbaraly, E.J. Brunner, M. Kivimäki, D.R. Witte, Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II Study. Lancet 373(9682), 2215-2221 (2009)
12. Y. Heianza, Y. Arase, K. Fujiahara, S.D. Hsieh, K. Satto, H. Tsuji, S. Kodama, N. Yahagi, H. Shimano, N. Yamada, S. Hara, H. Sone, Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes. The Toranomon Hospital Health Management Center Study 7 (TOPICS 7). Diabetes Care 35(5), 1050-1052 (2012)
13. A. Tirosh, I. Shai, D. Tekes-Manova, E. Isareli, D. Pereg, T. Shochat, I. Kochba, A. Rudich, Israeli Diabetes Research Group, Normal fasting plasma glucose levels and type 2 diabetes in young men. N. Engl. J. Med 353(14), 1454-62 (2005) [Erratum, N. Engl. J. Med. 354, 2401 (2006)]
14. L. Perreault, Q. Pan, K.J. Mather, K.E. Watson, R.F. Hamman, S.E. Kahn, Diabetes Prevention Program Research Group, Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379(9833), 2243-2251 (2012)
15. Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle interventions or metformin. N. Engl. J. Med. 346(6), 393-403 (2002)
16. M. Bergman, Inadequacies of absolute threshold levels for diagnosing prediabetes. Diabetes Metab. Res. Rev. 26(1), 3-6 (2010)
17. Y. Heianza, Y. Arase, K.H. Fujihara, H.K. Tsuji, K. Saito, S.D. Hsieh, S.D. Kodama, H.S. Shimano, N. Yamada, S. Hara, H. Sone, Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA1c and impaired fasting glucose the Toranomon Hospital Health Management Center Study 4 (TOPCS 4). Diabet. Med 29(9), e279-85 (2012). doi: 10.1111/j.1464-5491. 2012.03686
18. W.J. Kim, C.Y. Park, 1,5-Anhydroglucitol in diabetes mellitus. Endocrine (2012). doi: 10.1007/s12020-012-9760-6
19. A.G. Tabák, M. Carstensen, D.R. Witte, E.J. Brunner, M.J. Shipley, M. Jokela, M. Roden, M. Kivimäki, C. Herder, Adiponectin trajectories before type 2 diabetes diagnosis. Diabetes Care 35(12), 2540-2547 (2012)
20. M. Carstensen, C. Herder, M. Kivimäki, M. Jokela, M. Roden, M.J. Shipley, D.R. Witte, E.J. Brunner, A.G. Tabák, Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 59(5), 1222-1227 (2010)
21. R. Dankner, J. Roth, A. Danoff, Can 'personalized diagnostics' promote earlier intervention for dysglycaemia? Hypothesis ready for testing. Diabetes Metab. Res. Rev. 26(1), 7-9 (2010)